IL-IFT
9.5.2023 14:01:28 CEST | Business Wire | Press release
The Institute of Food Technologists (IFT), a nonprofit scientific organization committed to advancing the science of food and its application across the global food system, and the Seeding The Future Foundation are proud to announce the return of the annual Seeding The Future Global Food System Challenge. The Challenges invites scientists, engineers, innovators, entrepreneurs, and multidisciplinary teams from non-governmental organizations (NGOs), non-profits, social enterprises, universities, research institutions as well as small and emerging startups to submit their game-changing innovations that will help transform the global food system.
Now in its third year, the Challenge will once again award $1 million in grants and prizes via Seed Grants ($25,000 each), Growth Grants ($100,000 each), and Seeding The Future Grand Prizes ($250,000 each). Last year’s Growth Grant and Grand Prize winners included:
- Commercializing black soldier fly larvae as chicken feed to enhance egg nutrition and lower the cost of eggs in Rwanda. (Food Systems for the Future)
- Eliminating dangerous aflatoxins from smallholder supply chains starting with peanuts in Haiti. (Acceso)
- Accelerating the deployment of aquaponics that combine soilless crop production and fish farming to increase global food production in the face of climate change. (INMED Partnerships for Children)
- Community-led solar powered cold storage program to enable access to improved agricultural techniques and practices in rural developments. (Smart Villages Resource Group)
- Leveraging the US Postal Service to bring fresh produce from farms to front doors. (World Wildlife Fund)
“The Global Food System Challenge is meant to be a call to action to the global food community. More than 840 million people suffer from chronic hunger, severe undernutrition, and extreme poverty while more than 30% of food is wasted globally every year. Climate change, conflicts and poverty prevent equitable access to safe and nutritious food for many populations in both developed and developing regions. We urgently need impactful and transformative innovations that will lead to a sustainable food system and enable access of healthy, affordable, and appealing food that consumers trust,” said Bernhard van Lengerich, founder of Seeding The Future Foundation.
While application submissions open on June 1 and close on August 1, interested participants can review guidelines here to begin preparing their submission.
Since 2021, more than 1,500 submissions from 75 countries have been received from multidisciplinary teams from academic and research institutions, non-profits, and startups. The Challenge is funded by the Seeding The Future Foundation and hosted by IFT.
“The Seeding The Future Global Food System Challenge mirrors IFT’s mission and commitment to addressing food insecurity and ensuring a healthy future for our global food supply,” said IFT CEO Christie Tarantino-Dean. “We are thrilled to be partnering once again with Bernhard and the Seeding The Future Foundation on one of the most important showcases of food innovation and ingenuity.”
For more information, visit ift.org/food-system-challenge. Applicants needing additional support are encouraged to review Frequently Asked Questions.
About Institute of Food Technologists
The Institute of Food Technologists (IFT) is a global organization of approximately 12,000 individual members from more than 100 countries committed to advancing the science of food. Since 1939, IFT has brought together the brightest minds in food science, technology and related professions from academia, government, and industry to solve the world’s greatest food challenges. IFT works to ensure that its members have the resources they need to learn, grow and advance the science of food as the population and the world evolve. IFT believes that science is essential to ensuring a global food supply that is sustainable, safe, nutritious, and accessible to all. For more information, please visit ift.org.
About Seeding The Future Foundation
The Seeding The Future Foundation is a private, non-profit organization motivated by its core value that everyone should always have equitable access to safe, nutritious, affordable, appealing, and trusted food. It seeks to inspire innovative solutions that can help transform the global food system to be more sustainable and benefit the health of people and the environment. The Foundation provides seed funding and support to promising ideas and high impact innovations to improve food systems globally, technologies to reduce post-harvest losses in developing regions, as well as foundational work in academia and research. For more information, please visit seedingthefuture.org.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230509005101/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom